In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
299
Universitätsklinikum der RWTH Aachen
Aachen, Germany
Praxis Dr. Heidenreich
Böblingen, Germany
Universitätsklinikum Carl Gustav Carus
Dresden, Germany
"Patient Global Impression of Change" (PGI-C) at visit 4
It is the statistical comparison between the placebo group and the memantine group.The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model.
Time frame: 12 weeks
Change from baseline to visit 3 and 5 of Patient Global Impression of Change (PGI-C)
Time frame: 16 weeks
Change from baseline to visit 4 in "Everyday Cognition 39" (ECog 39) total score
Time frame: 12 weeks
Change from baseline to visit 4 in "Hospital Anxiety and Depression Scale" (HADS) Score
Time frame: 12 weeks
Change from baseline to visit 3, 4, 5 of "Computer-based Neuropsychological Test Battery (C-NTB) by CogState Ltd.
Time frame: 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Praxis Dr. Albrecht
Ellwangen, Germany
Praxis Dr. Reifschneider
Erbach im Odenwald, Germany
Klinische Forschung Hannover-Mitte
Hanover, Germany
ZSL Zentrum für medizinische Studien in Leipzig
Leipzig, Germany
Klinische Forschung Berlin-Mitte
Mitte, Germany
Praxis Dr. Pauls
München, Germany
Praxis Dr. Kühn
Oranienburg, Germany
...and 4 more locations